Evidence map›Paper›PMID 36689044›Full record

ArticleIn vitro cellular & developmental biology. Animal2023

Cathepsin K degrades osteoprotegerin to promote osteoclastogenesis in vitro.

Ryota Kawai, Risa Sugisaki, Yoichi Miyamoto, Fumiko Yano, Kiyohito Sasa, Erika Minami, Koutaro Maki, Ryutaro Kamijo

Abstract read
PubMed Publisher
In one paragraph

Article in In vitro cellular & developmental biology. Animal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ryota KawaiDepartment of Biochemistry, Showa University School of Dentistry, Tokyo, Japan.
Risa SugisakiDepartment of Biochemistry, Showa University School of Dentistry, Tokyo, Japan.
Yoichi MiyamotoDepartment of Biochemistry, Showa University School of Dentistry, Tokyo, Japan. yoichim@dent.showa-u.ac.jp.
Fumiko YanoDepartment of Biochemistry, Showa University School of Dentistry, Tokyo, Japan.
Kiyohito SasaDepartment of Biochemistry, Showa University School of Dentistry, Tokyo, Japan.
Erika MinamiDepartment of Biochemistry, Showa University School of Dentistry, Tokyo, Japan.
Koutaro MakiDepartment of Orthodontics, Showa University School of Dentistry, Tokyo, Japan.
Ryutaro KamijoDepartment of Biochemistry, Showa University School of Dentistry, Tokyo, Japan.
Showa University · JPShowa Pharmaceutical University · JPTokyo Medical University · JP

Funding

Japan Society for the Promotion of Science 21K09835Japan Society for the Promotion of Science 21K16936Japan Society for the Promotion of Science 22H03256
6 · The paper itself

Abstract

Osteoblasts produce the receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin, the inducer and the suppressor of osteoclast differentiation and activation. We previously proposed that the degradation of osteoprotegerin by lysine-specific gingipain of Porphyromonas gingivalis and neutrophil elastase is one of the mechanisms of bone resorption associated with infection and inflammation. In the present study, we found that cathepsin K (CTSK) also degraded osteoprotegerin in an acidic milieu and the buffer with a pH of 7.4. The 37 k fragment of osteoprotegerin produced by the reaction with CTSK was further degraded into low molecular weight fragments, including a 13 k fragment, depending on the reaction time. The N-terminal amino acid sequence of the 37 k fragment matched that of the intact osteoprotegerin, indicating that CTSK preferentially hydrolyzes the death domain-like region of osteoprotegerin, not its RANKL-binding region. The 13 k fragment of osteoprotegerin was the C-terminal 13 k portion within the RANKL-binding region of the 37 k fragment. Finally, CTSK restored RANKL-dependent osteoclast differentiation that was suppressed by the addition of osteoprotegerin. Collectively, CTSK is a possible positive regulator of osteoclastogenesis.

Indexed as

OsteogenesisOsteoprotegerinAnimalsCarrier ProteinsCathepsin KCell DifferentiationGlycoproteinsMembrane GlycoproteinsOsteoclastsRANK LigandReceptor Activator of Nuclear Factor-kappa BReceptors, Cytoplasmic and NuclearCarrier ProteinsCathepsin KGlycoproteinsMembrane GlycoproteinsOsteoprotegerinRANK LigandReceptor Activator of Nuclear Factor-kappa BReceptors, Cytoplasmic and NuclearCathepsin KOsteoclast differentiationOsteoprotegerinProteolysis

Identifiers

PMID36689044
OpenAlexW4317780973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.